Clinical trial · Observational
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Combining Contrast-Enhanced Mammography and Radio-active Free Magnetic Seed Localization of Non-palpable Breast Tumors: A Feasibility Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rationale: Breast cancer patients are increasingly treated with neoadjuvant chemotherapy for various reasons. These women receive chemotherapy before any surgery is performed. Many of these tumors need preoperative seed localization to help guide the surgeons to the site of the tumor within the breast. The interest is shifting towards to use of non-radioactive seeds, such as the magnetic seeds used in this study. A drawback of these seeds is the fact that they cause large susceptibility artifacts on (magnetic!) MRI of the breast. Breast MRI is the most accurate modality to monitor response to therapy of these women. CEM, an emerging breast imaging technique, has shown to achieve comparable results with regard to response monitoring but uses no magnetic fields. Hence, CEM might be an attractive alternative response monitoring tool in patients treated with neoadjuvant chemotherapy and having a magnetic seed a surgical marker. To this point, however, no study in humans has confirmed that this is indeed the case. Objective: To test whether the use of magnetic localization seeds causes image artifacts on CEM. Study design: Observational feasibility study. Study population: Women (\>18 years) able to provide written informed consent and recently diagnosed with (non-palpable) breast cancer or ductal carcinoma in situ (DCIS), who are primarily treated with surgery. Intervention (if applicable): Image-guided placement of a magnetic seed (Sirius Pintuition) prior to surgery, including control imaging to confirm the correct location of the seed relative to the breast abnormality. In usual patient care this is performed with full-field digital mammography (FFDM), but in this study this control image will be performed with the system in 'contrast-enhanced mammography' or CEM mode, but without using intravenous administration of iodinated contrast agent because the purpose is not repetition of diagnostic imaging, but to rule out any artifacts caused by the seed on CEM. The investigators estimate to include twenty patients to confidently test the hypothesis that magnetic seeds do not cause disturbing artifacts on CEM examinations. Main study parameters/endpoints: The primary study aim will be to test whether the magnetic seeds caused any disturbing artifacts on CEM images. As secondary study, the investigators will document technical success rate of seed deployment and retrieval during surgery, including the assessment of the surgical margins (positive or negative).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pintuition | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients receiving seed localization
- description
- Patients receiving seed localization
- interventionNames
- Device: Pintuition
Primary outcomes (2)
- measure
- Assessment of image artifacts
- timeFrame
- 1 day
- description
- Main study endpoint will be the assessment of the occurrence of image artifacts, which will be scored by blinded radiologists in the following way: if there are any artifacts present in the image (yes/no) and caused by the magnetic seed
- measure
- Influence of image artifacts
- timeFrame
- 1 day
- description
- If primary outcome measure #1 is answered with yes: are the artifacts influencing the overall image quality (yes/no)?
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Included are non-pregnant women (\>18 years of age), * Recently diagnosed with non-palpable invasive breast cancer or DCIS, requiring primary surgical treatment. * Only women able to provide written informed consent will be considered for this study. Exclusion Criteria: \- Excluded are women not meeting the inclusion criteria.
References
Publications (0)
Data not yet available